Schwager K, Villa A, R ösli C, Neri D, Rösli-Khabas M, Moser G. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol. 2011 May 8;3:25.

Conclusions These results suggests that an individualized treatment procedure (e.g., choice of L19, F8 or F 16 based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the best possible antibody to any given patient.
Source: Head and Neck Oncology - Category: Cancer & Oncology Source Type: research